[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2519446T3 - Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP - Google Patents

Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP Download PDF

Info

Publication number
ES2519446T3
ES2519446T3 ES07818108.8T ES07818108T ES2519446T3 ES 2519446 T3 ES2519446 T3 ES 2519446T3 ES 07818108 T ES07818108 T ES 07818108T ES 2519446 T3 ES2519446 T3 ES 2519446T3
Authority
ES
Spain
Prior art keywords
biaryl
derivatives
amino
preparation
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07818108.8T
Other languages
English (en)
Inventor
David Hook
Bernhard Wietfeld
Matthias Lotz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37814152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2519446(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2519446T3 publication Critical patent/ES2519446T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/32—Preparation of optical isomers by stereospecific synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un proceso para producir un compuesto de acuerdo con la fórmula (I) o una sal del mismo, en donde R1 y R1` son independientemente hidrógeno o un grupo protector amina, y R2 es un grupo carboxilo o un grupo éster, que comprende hacer reaccionar un compuesto de acuerdo con la fórmula (ii), o una sal del mismo, en donde R1, R1' y R2 son como se definieron anteriormente, con hidrógeno en presencia de un catalizador de metal de transición y un ligando quiral, en donde el metal de transición se selecciona del grupo 7, 8 o 9 de la tabla periódica.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES07818108.8T 2006-09-13 2007-09-11 Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP Active ES2519446T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06120576 2006-09-13
EP06120576A EP1903027A1 (en) 2006-09-13 2006-09-13 Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
PCT/EP2007/007913 WO2008031567A1 (en) 2006-09-13 2007-09-11 Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors

Publications (1)

Publication Number Publication Date
ES2519446T3 true ES2519446T3 (es) 2014-11-07

Family

ID=37814152

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07818108.8T Active ES2519446T3 (es) 2006-09-13 2007-09-11 Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP

Country Status (29)

Country Link
US (2) US20090326066A1 (es)
EP (2) EP1903027A1 (es)
JP (1) JP5455627B2 (es)
KR (1) KR101401118B1 (es)
CN (1) CN101516831B (es)
AU (1) AU2007296889B2 (es)
BR (1) BRPI0716990A2 (es)
CA (1) CA2662393C (es)
CO (1) CO6190550A2 (es)
CY (1) CY1115696T1 (es)
DK (1) DK2066618T3 (es)
ES (1) ES2519446T3 (es)
GT (1) GT200900058A (es)
HK (1) HK1131381A1 (es)
HR (1) HRP20140984T1 (es)
IL (1) IL196925A (es)
MA (1) MA30724B1 (es)
MX (1) MX2009002746A (es)
MY (1) MY146660A (es)
NO (1) NO341967B1 (es)
NZ (1) NZ574665A (es)
PL (1) PL2066618T3 (es)
PT (1) PT2066618E (es)
RU (1) RU2469019C2 (es)
SG (1) SG177205A1 (es)
SI (1) SI2066618T1 (es)
TN (1) TN2009000077A1 (es)
WO (1) WO2008031567A1 (es)
ZA (1) ZA200900779B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2121578T3 (en) 2007-01-12 2016-12-05 Novartis Ag A process for the preparation of 4-biphenyl-4-amino-2-methylpentanoic acid
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
ES2523734T3 (es) 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
PL2526088T3 (pl) * 2010-01-22 2016-01-29 Novartis Ag Produkty pośrednie inhibitorów obojętnej endopeptydazy oraz sposób ich wytwarzania
AU2011295170B2 (en) * 2010-08-23 2014-12-18 Novartis Ag Process for the preparation of intermediates for the manufacture of NEP inhibitors
SI2609071T1 (sl) * 2010-08-23 2017-01-31 Novartis Ag Novi postopek za pripravo intermediatov, uporabnih za izdelavo NEP inhibitorjev
CN103080077B (zh) * 2010-08-23 2015-06-10 诺华股份有限公司 用于制造nep抑制剂的中间体的制备工艺
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AR092278A1 (es) * 2012-08-31 2015-04-08 Novartis Ag Proceso de obtencion de derivados n-acilicos de bifenil-alanina e intermediarios relacionados
US9102635B2 (en) 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
JP2016528271A (ja) * 2013-08-21 2016-09-15 ディーピーエックス ホールディングス ビー．ブイ． □新規な中間体を経由するビフェニルアラニノールの合成
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
CN106458857A (zh) * 2014-08-27 2017-02-22 上海翰森生物医药科技有限公司 AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (en) 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
PT3218351T (pt) 2014-11-14 2019-09-26 Zentiva Ks Um método para a preparação, isolamento e purificação de formas farmaceuticamente aplicáveis de ahu-377
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
CN105884644B (zh) * 2015-02-15 2020-06-09 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐优势形态及其制备方法
CN106146351B (zh) * 2015-04-03 2020-09-11 博瑞生物医药（苏州）股份有限公司 制备联芳基取代的4-氨基-丁酸或其衍生物的方法
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
CN106187808A (zh) * 2015-05-08 2016-12-07 苏州鹏旭医药科技有限公司 Ahu-377的制备方法、ahu-377中间体及ahu-377中间体的制备方法
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
CN107980038B (zh) 2015-07-02 2021-04-27 诺华股份有限公司 沙库巴曲钙盐
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
CN105061263B (zh) * 2015-08-11 2017-03-15 苏州楚凯药业有限公司 一种nep抑制剂中间体的制备方法
CN105085322B (zh) * 2015-08-15 2017-10-03 浙江永宁药业股份有限公司 Ahu‑377中间体的制备方法及其中间体和中间体的制备方法
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药（湖北）有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033128A1 (en) * 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
CN105152980B (zh) * 2015-09-11 2017-03-29 浙江永宁药业股份有限公司 N‑叔丁氧羰基‑（4s）‑（对苯基苯基甲基）‑4‑氨基‑（2r）‑甲基丁酸的手性制备方法
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
CN105523964B (zh) * 2015-12-09 2017-05-24 苏州楚凯药业有限公司 一种抗心衰药物中间体的制备方法
EP3386955B1 (en) 2015-12-10 2020-08-05 Novartis AG Intermediates for the preparation of sacubitril and their preparation
BR112018011788A2 (pt) 2015-12-11 2018-12-04 Zentiva Ks formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CN106977415B (zh) * 2016-01-15 2021-03-26 广东东阳光药业有限公司 一种沙库必曲的中间体及其制备方法
WO2017141193A1 (en) * 2016-02-16 2017-08-24 Sun Pharmaceutical Industries Limited Process for the preparation of sacubitril or salts thereof
CN105924355B (zh) * 2016-05-11 2018-08-17 浙江宏元药业有限公司 沙库比曲中间体及沙库比曲中间体和沙库比曲的制备方法
CN109415308B (zh) 2016-07-05 2022-09-06 诺华股份有限公司 用于早期沙卡布曲中间体的新方法
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
CN106380421B (zh) * 2016-08-26 2017-12-08 中国科学院上海有机化学研究所 沙库必曲的合成方法
EP3522886A4 (en) 2016-10-10 2020-02-19 Laurus Labs Limited STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
CN106631903A (zh) * 2016-12-16 2017-05-10 重庆市碚圣医药科技股份有限公司 一种lcz‑696关键中间体的制备方法
ES2883363T3 (es) * 2016-12-23 2021-12-07 Novartis Ag Proceso nuevo para intermedios iniciales de sacubitrilo
CN107011203B (zh) * 2017-04-28 2019-03-29 江苏阿尔法药业有限公司 一种lcz696中间体ahu-377的制备方法
CN107522628A (zh) * 2017-09-20 2017-12-29 吉尔生化（上海）有限公司 一种l‑3‑（6‑乙酰基‑2‑萘胺基）‑2‑氨基丙酸的合成方法
CN108084058A (zh) * 2017-12-15 2018-05-29 江苏中邦制药有限公司 一种lcz696中间体的制备方法
CN108373423B (zh) * 2018-04-28 2020-10-23 成都苑东生物制药股份有限公司 一种沙库比曲缬沙坦复合物和/或共晶关键中间体沙库比曲钙的制备方法
CN109400504A (zh) * 2018-12-11 2019-03-01 重庆三圣实业股份有限公司 Lcz696中间体非对映异构体的分离纯化方法
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法
CN111748590B (zh) * 2019-03-29 2024-05-28 弈柯莱(台州)药业有限公司 转氨酶在制备Sacubitril中间体中的应用
CN110128298B (zh) * 2019-06-13 2021-08-03 南京一心和医药科技有限公司 一种沙库巴曲中间体的合成方法
CN112574132B (zh) * 2019-09-30 2024-02-27 广东东阳光药业股份有限公司 一种沙库必曲缬沙坦钠的制备方法
CN113135836A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种沙库巴曲钙盐的制备方法
CN113321600B (zh) * 2020-02-28 2024-06-14 四川科伦药物研究院有限公司 制备手性联芳基取代的4-氨基-丁酸及其衍生物的方法
CN113387841A (zh) * 2020-03-13 2021-09-14 凯特立斯（深圳）科技有限公司 一种沙库必曲中间体的合成方法
CN111269148B (zh) * 2020-04-08 2022-02-08 台州职业技术学院 一种沙库比曲中间体的制备方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
CN112745246A (zh) * 2020-12-30 2021-05-04 重庆市碚圣医药科技股份有限公司 一种沙库必曲中间体的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
JP3020128B2 (ja) * 1994-03-08 2000-03-15 高砂香料工業株式会社 光学活性カルボン酸の製造法
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US6214763B1 (en) * 1997-05-20 2001-04-10 Firmenich Sa Ruthenium catalysts and their use in the asymmetric hydrogenation of weakly coordinating substrates
ES2219493T3 (es) * 2000-01-27 2004-12-01 Warner-Lambert Company Sintesis asimetrica de la pregabalina.
GB0026890D0 (en) * 2000-11-03 2000-12-20 Ici Plc Catalyst
AR043515A1 (es) * 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2005016178A2 (en) 2003-08-04 2005-02-24 Auragin, Inc. Cochlear ear implant
EP1667957A2 (en) * 2003-09-25 2006-06-14 Warner-Lambert Company LLC Amino acids with affinity for the alpha2delta-protein
US20080026933A1 (en) * 2004-07-05 2008-01-31 Benoit Pugin 1,1'-Diphosphinoferrocenes Having 2,2'-Bound Achiral Or Chiral Radicals
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
WO2006057904A1 (en) * 2004-11-23 2006-06-01 Merck & Co., Inc. Stereoselective preparation of 4-aryl piperidine amides by asymmetric hydrogenation of a prochiral enamide and intermediates of this process
AT501193B1 (de) * 2004-12-27 2007-03-15 Dsm Fine Chem Austria Gmbh Verfahen zur übergangsmetall - katalysierten asymmetrischen hydrierung von acrylsäurederivaten

Also Published As

Publication number Publication date
TN2009000077A1 (en) 2010-08-19
IL196925A0 (en) 2009-11-18
NO20091242L (no) 2009-03-25
US20090326066A1 (en) 2009-12-31
NZ574665A (en) 2012-03-30
JP5455627B2 (ja) 2014-03-26
SG177205A1 (en) 2012-01-30
EP1903027A1 (en) 2008-03-26
GT200900058A (es) 2010-03-11
NO341967B1 (no) 2018-03-05
CN101516831A (zh) 2009-08-26
WO2008031567A1 (en) 2008-03-20
HK1131381A1 (en) 2010-01-22
MX2009002746A (es) 2009-03-26
KR20090076910A (ko) 2009-07-13
RU2009113666A (ru) 2010-10-20
KR101401118B1 (ko) 2014-05-29
RU2469019C2 (ru) 2012-12-10
MA30724B1 (fr) 2009-09-01
PL2066618T3 (pl) 2015-01-30
PT2066618E (pt) 2014-09-10
SI2066618T1 (sl) 2014-11-28
JP2010503628A (ja) 2010-02-04
DK2066618T3 (da) 2014-09-22
ZA200900779B (en) 2009-12-30
US8946481B2 (en) 2015-02-03
EP2066618B1 (en) 2014-07-23
EP2066618A1 (en) 2009-06-10
BRPI0716990A2 (pt) 2014-02-04
AU2007296889B2 (en) 2012-03-01
CA2662393A1 (en) 2008-03-20
WO2008031567B1 (en) 2008-05-08
MY146660A (en) 2012-09-14
CA2662393C (en) 2015-11-03
CO6190550A2 (es) 2010-08-19
US20130066101A1 (en) 2013-03-14
IL196925A (en) 2013-10-31
AU2007296889A1 (en) 2008-03-20
HRP20140984T1 (hr) 2014-12-05
CY1115696T1 (el) 2017-01-25
CN101516831B (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
ES2519446T3 (es) Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP
CO6290677A2 (es) Procesos e intermediarios para la preparación de derivados de acido 5-bifenil-4-il-2-metilpentanoico.
ES2495815T3 (es) Proceso para la síntesis de lacosamida
RS52542B (en) NEW PROCEDURE FOR THE SYNTHESIS OF IVABRADINE AND ITS ADDITIONAL SALTS WITH PHARMACEUTICALLY ACCEPTABLE ACID
ES2568009T3 (es) Procedimiento para la absorción de CO2 a partir de una mezcla gaseosa con un medio de absorción que contiene aminas
ECSP067053A (es) 1-aza-biciclo[3.3.1]nonanos
GEP20115306B (es)
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
RU2013112946A (ru) Способ получения промежуточных соединений для получения ингибиторов nep
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
MY145992A (en) New process for the resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3-5-trien-7-yl)nitrile and application in the synthesis of ivabradine
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
CU20100099A7 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
DE602006010584D1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
ES2630392T3 (es) Síntesis asimétrica de una pirrolidina-2-carboxamida sustituida
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
AR066054A1 (es) Proceso para preparar galantamina
CO6630099A2 (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metolpirroidin-2-il]etil}-1.2.3.4-tetrahidroisoquinolin-7-sulfonamida
ES2568927T3 (es) Proceso para fabricar derivados de adamantano con alto rendimiento
ES2541401T3 (es) Nuevos derivados de isoquinolina disustituidos en 6,7 y su uso
MX2010004261A (es) Acidos carboxilicos bifenil y derivados de los mismos.
ATE542822T1 (de) Stereoselektive synthese bestimmter trifluormethyl-substituierter alkohole